Immune response to pre-exposure rabies vaccination via intradermal route compared to intramuscular in kidney transplant recipients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200716006

Enrollment

Unknown

Registered

2020-07-16

Start date

2020-02-03

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rabies neutralizing antibody Rabies vaccination Kidney transplant recipient Immune response

Interventions

2 sites of rabies vaccine 0.1 ml via ID route at both arms day 0&#44

7 and 28,1 site of rabies vaccine 0.5 ml via IM route at deltoid on day 0&#44

7 and 28

Active Comparator Biological/Vaccine,Active Comparator Biological/Vaccine

Intradermal vaccination,Intramuscular vaccination

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients aged above 18 years who underwent kidney transplantation more than 3 months prior with functioning renal allograft at the time of randomization.

Exclusion criteria

Exclusion criteria: Patients who had previous rabies vaccination, intravenous immunoglobulin within 3 months, acute febrile illness within 1 week, detectable cytomegalovirus (CMV) viremia, CMV disease or contraindications for ID or IM injections were excluded

Design outcomes

Primary

Measure	Time frame
Seroconversion rate of participants Day 42 after the first vaccination Rabies neutralizing antibody >0.5 IU/ml	—

Secondary

Measure	Time frame
Geometric mean titers Day 42 after 1st vaccination RVNA	—

Countries

Thailand

Contacts

Public ContactPawat Phuensan

King Chulalongkorn Memorial Hospital

pawat.phuensan@gmail.com0815625652

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026